A composition has an enzyme that is able to convert a substrate to release hydrogen peroxide; a substrate for the enzyme; and a superabsorbent component, such as a superabsorbent polymer. The composition is in the form of a powder and may form a gel on contact with water.

Compositions for enhancing wound healing are disclosed herein. Also disclosed are methods of making the compositions and methods of using the compositions for the prevention of biofilm formation and for the inhibition of pathogen growth and proliferation.

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction.

Provided is a method of forming a fibrinogen hydrogel composition, the method including providing a fibrinogen hydrogel or precursor thereof, comprising fibrinogen hydrogel forming salt. The fibrinogen hydrogel forming salt concentration is greater than or equal to the threshold concentration to form a fibrinogen hydrogel. The method further includes denaturing the fibrinogen hydrogel such as by heating. The method optionally further includes combining the fibrinogen hydrogel with a carrier material. When present, the concentration of the carrier material typically ranges from 0.1 to about 50 wt.-%. The method further includes reducing the salt concentration below the threshold concentration to form a fibrinogen hydrogel.

A method of forming a fibrin hydrogel composition including providing one or more unitary masses of a fibrin hydrogel, dividing at least one of the unitary masses of the fibrin hydrogel into a multiplicity of smaller pieces of the fibrin hydrogel, and recombining at least a portion of the smaller pieces into a cohesive mass. Dividing at least one of the unitary masses of fibrin hydrogel into a multiplicity of smaller pieces may include shearing or cutting the unitary masses to form an aqueous dispersion of the fibrin hydrogel in an aqueous medium. The aqueous dispersion of fibrin hydrogel may be applied to a substrate on a roller or an endless belt, and is optionally overlaid by a scrim. The cohesive mass of fibrin hydrogel, which may be formed by removing at least a portion of the aqueous medium from the aqueous dispersion of the smaller pieces of the fibrin hydrogel, finds uses in wound dressing articles.

Fibrin Sealant products are used for topical hemostasis and tissue adherence. They are composed of two main reagents, fibrinogen and thrombin. When mixed in solution fibrinogen is converted to fibrin upon the addition of activated thrombin. Therefore typically these two components are stored separately in a lyophilized or liquid state, and mixed, upon or immediately before, application to a patient. While effective, these products require significant preparation that must take place immediately before application, thus delaying treatment and limiting the use of these haemostatic products to the treatment of mild forms of low pressure and low volume bleeding. Attempts to eliminate this delay and expand the usefulness and effectiveness of these products have resulted in products produced by processes that require the separation of these components and their deposition in distinct layers within the product. The processes described herein permit the mixing of fibrinogen and thrombin during product manufacture, without excessive fibrin formation. The resulting pre-mixed fibrin sealant material can then be stored in either a frozen or dried state, or suspended in a non-aqueous environment. Activation of the material to form therapeutic fibrin sealant is accomplished by permitting the product to thaw (if frozen) or by the addition of water or other aqueous fluid, including blood, or other bodily fluids, if dried or suspended in a non-aqueous environment. The resulting material can be used to make a product in which a pre-mixed form of activatable fibrin sealant is a desired component.

Compositions for enhancing wound healing are disclosed herein. Also disclosed are methods of making the compositions and methods of using the compositions for the prevention of biofilm formation and for the inhibition of pathogen growth and proliferation.

Disclosed are solid and frozen haemostatic materials and dressings consisting essentially of a fibrinogen component and a fibrinogen activator. Also disclosed are methods of treating internal wounded tissue in a mammal by applying one or more of these haemostatic materials and dressings.

A hemostatic product that includes a dry fibrinogen mixture, a dry thrombin mixture and a biologically tolerable liquid. The dry fibrinogen mixture includes fibrinogen and at least one fibrinogen stabilizer. The dry thrombin mixture includes thrombin and at least one thrombin stabilizer. The biologically tolerable liquid is mixed with the dry fibrinogen mixture and the dry thrombin mixture to form the hemostatic product.

The present invention provides compositions and methods to enhance cutaneous wound healing in subjects afflicted with, or at risk for, a pulmonary infection and/or a pulmonary injury. More specifically, the embodiments of the present invention relate to using fibrin carrier as a vehicle to topically deliver one or more chemokine onto a cutaneous wound so as to accelerate wound healing.